Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1391349
This article is part of the Research Topic Pancreatic, Lung, and Stomach Cancer Awareness Month View all 4 articles

A case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib

Provisionally accepted
Xiaoting Chen Xiaoting Chen 1Wen Zhao Wen Zhao 2Hejiang Yu Hejiang Yu 3Shuang Wang Shuang Wang 2Chengjun Wang Chengjun Wang 2Xue Meng Xue Meng 4*Jisheng Li Jisheng Li 2*
  • 1 Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Taian, China
  • 2 Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China
  • 3 Department of Oncology, Yunyang County People's Hospital, Yunyang, China
  • 4 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China

The final, formatted version of the article will be published soon.

    Lung squamous cell carcinoma (LUSC) is the second most common pathological type of non-small cell lung cancer (NSCLC). However, compared with lung adenocarcinoma (LUAD), the incidence of driver gene mutations in LUSC is relatively lower and treatment options for LUSC patients are very limited.We described a LUSC patient with a novel FGFR3-IER5L fusion revealed by next generation sequencing in this report. The patient refused surgery, radiotherapy or chemotherapy and received anlotinib treatment.Anlotinib is a small molecular multi-target tyrosine kinase inhibitor, which can inhibit the activity of kinases including vascular endothelial growth factor receptor 2/3 (VEGFR2/3), fibroblast growth factor receptor 1-4 (FGFR1-4), platelet-derived growth factor receptor α/β (PDGFRα/β), and c-Kit. The patient achieved partial response and the progression-free survival was 114 days.

    Keywords: Lung squamous cell carcinoma, FGFR3-IER5L fusion, Anlotinib, multi-target tyrosine kinase inhibitor, Driver gene mutation

    Received: 25 Feb 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Chen, Zhao, Yu, Wang, Wang, Meng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xue Meng, Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province, China
    Jisheng Li, Department of Medical Oncology, Qilu Hospital, Shandong University, Jinan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.